---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Positional therapy"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Positional therapy. Topics: VA/DoD guideline: positional therapy for positional OSA (weak for), pooled AHI with hypopnea scoring rule not stated; ERS guideline: vibratory positional therapy or CPAP in mild or moderate position-dependent OSA (conditional recommendation, very low certainty of evidence), hypopnea scoring rule not stated; Cochrane review: positional therapy compared with CPAP and with inactive control, pooled AHI with hypopnea scoring rule not stated. 3 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/positional-therapy"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Positional therapy

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Positional Therapy

<a id="topic-2.2.2.1.4-1"></a>

### VA/DoD guideline: positional therapy for positional OSA (weak for), pooled AHI with hypopnea scoring rule not stated

> “21. For treatment of positional obstructive sleep apnea, we suggest positional therapy. Weak for”
> “Finally, it was associated with an improvement in AHI compared with control (Mean Difference (MD) −7.38 events per hour).”
> “Positional therapy was not associated with improved functional outcomes, overall quality of life (QoL) or sleep-related QoL.”
> “The Work Group’s confidence in the quality of the evidence was very low.”
> “When assessing resource use, positional therapy is a low cost, accessible treatment option.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.4-2"></a>

### ERS guideline: vibratory positional therapy or CPAP in mild or moderate position-dependent OSA (conditional recommendation, very low certainty of evidence), hypopnea scoring rule not stated

> “We suggest either positional therapy using vibratory devices or CPAP among adult patients with mild or moderate position-dependent OSA as defined by a supine AHI at least twice as high as the nonsupine AHI and no relevant nonsupine AHI (<15 events·h−1) (conditional recommendation for either the intervention or CPAP, very low certainty of evidence) (supplementary table e18).”
> “In patients with mild positional OSA, we suggest using either vibrational positional therapy or MAD (conditional recommendation for either the intervention or control, very low certainty of evidence) (supplementary table e19).”
> “However, positional therapy was superior in terms of compliance (CPAP 4.9 h per night, positional therapy +2.5 h per night; 95% CI 1.3–4.6 h per night).”
> “In this context, other studies found the TBT to be associated with low long-term compliance, mostly due to a lack of subjective comfort [85–87].”

Source: [Randerath et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9489103/)

<a id="topic-2.2.2.1.4-3"></a>

### Cochrane review: positional therapy compared with CPAP and with inactive control, pooled AHI with hypopnea scoring rule not stated

> “We included eight studies. The studies randomised 323 participants into two types of interventions.”
> “Two studies showed that CPAP produced a greater reduction in Apnoea‐Hypopnoea Index (AHI) with a mean difference (MD) of 6.4 events per hour (95% CI 3.00 to 9.79; low‐certainty evidence) compared to positional therapy.”
> “Positional therapy showed a reduction in AHI compared with control (MD −7.38 events per hour, 95% CI −10.06 to −4.7; low‐certainty evidence).”
> “All the studies were of short duration. We are unable to comment on the long‐term effects of the therapies.”

Source: [Srijithesh et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6491901/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
